1-8 of 8
Mark Merchant
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma

Available to Purchase
Paul Rossman, Tanja S. Zabka, Audrey Ruple, Dietrich Tuerck, José A. Ramos-Vara, Liling Liu, Rodrigo Mohallem, Mark Merchant, Jackeline Franco, Christopher M. Fulkerson, Ketaki P. Bhide, Matthew Breen, Uma K. Aryal, Elaine Murray, Noel Dybdal, Sagar M. Utturkar, Lindsey M. Fourez, Alexander W. Enstrom, Deepika Dhawan, Deborah W. Knapp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (11): 2177–2188.
https://doi.org/10.1158/1535-7163.MCT-20-0893
Published: 01 November 2021
View articletitled, Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Open the PDF for Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma

Free
Nisebita Sahu, Emily Chan, Felix Chu, Thinh Pham, Hartmut Koeppen, William Forrest, Mark Merchant, Jeff Settleman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (9): 1729–1738.
https://doi.org/10.1158/1535-7163.MCT-17-0009
Published: 04 September 2017
View articletitled, Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
Open the PDF for Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity

Free
Yiyuan Yin, Stevan Djakovic, Scot Marsters, Janet Tien, Jing Peng, Jarrod Tremayne, Genee Lee, Richard M. Neve, Yan Wu, Mark Merchant, Avi Ashkenazi, Paul J. Carter
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (10): 2270–2278.
https://doi.org/10.1158/1535-7163.MCT-14-1050
Published: 05 October 2015
View articletitled, Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Open the PDF for Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Free
Melissa R. Junttila, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Michelle A. Nannini, Dorothy French, Richard Carano, Mark Merchant, Klaus P. Hoeflich, Mallika Singh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (1): 40–47.
https://doi.org/10.1158/1535-7163.MCT-14-0030
Published: 13 January 2015
View articletitled, Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Open the PDF for Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab

Free
Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant, Judy C. Young
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 540–552.
https://doi.org/10.1158/1535-7163.MCT-13-0494
Published: 09 February 2014
View articletitled, Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
Open the PDF for Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab in another window
Includes: Supplementary data
Journal Articles

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Free
Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner, Priti S. Hegde
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1122–1130.
https://doi.org/10.1158/1535-7163.MCT-13-0015
Published: 09 June 2013
View articletitled, HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
Open the PDF for HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract A250: Preclinical combination efficacy and identification of biomarkers of MEK and PI3K inhibitors in phase I

Free
Klaus Hoeflich, Mark Merchant, Doug Den Otter, Jocelyn Chan, Emily Chan, Christine Orr, Lori Friedman, Iris Chan, John Prescott, Leanne Berry, Hartmut Koeppen, Marcia Belvin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A250.
https://doi.org/10.1158/1535-7163.TARG-09-A250
Published: 10 December 2009
View articletitled, Abstract A250: Preclinical combination efficacy and identification of biomarkers of MEK and PI3K inhibitors in phase I
Journal Articles

HGF and cMet extracellular domain levels in serum versus plasma from mice, monkeys, and humans

Free
Elaine Mai, Mark Merchant, Wai Lee Wong, Judy Young
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C154.
Published: 01 November 2007
View articletitled, HGF and cMet extracellular domain levels in serum versus plasma from mice, monkeys, and humans